Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GPHN
REST API REST API
Homo sapiens
GPHN is differentially expressed in 248 experiments: 116 organism parts: bone marrow, liver, ... (114 more);, 175 disease states: normal, colon carcinoma, ... (173 more);, 71 cell types 436 cell lines 40 compound treatments and 70 other conditions.
Synonyms KIAA1385
Orthologs Gphn (Rattus norvegicus)   ENSCING00000002784 (Ciona intestinalis)   GPHN (Bos taurus)   GPHN (Gallus gallus)   Gphn (Mus musculus)   gphnb (Danio rerio)   GPHN (2 of 2) (Danio rerio)   cin (Drosophila melanogaster)   gphn (Xenopus laevis)   GPHN (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, molybdopterin cofactor biosynthetic process, cytoskeleton, cytoplasm, intracellular, postsynaptic membrane, metal ion binding, cell junction, Mo-molybdopterin cofactor biosynthetic process, ATP binding, nucleotide binding, synapse, transferase activity, vitamin metabolic process, establishment of synaptic specificity at neuromuscular junction, water-soluble vitamin metabolic process
InterPro Term MoeA_linker/N, MoeA_C_domain_IV, Mo_cofactor_synthesis, Mopterin-bd
UniProt Accession Q9NQX3, F5H2D3, F5H039, F8W7D6
Gene-Disease Assocation MOLYBDENUM COFACTOR DEFICIENCY, HYPEREKPLEXIA, HEREDITARY
Search EB-eye ENSG00000171723
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
SKBR3
2
E-MEXP-440, E-MTAB-62
T84
2
E-MTAB-37, E-GEOD-1474
430 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, E-GEOD-13987, ... (37 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
germ cell
1
E-MTAB-25
CD8+ T cell
1
E-GEOD-6740
neurosphere cell
1
E-MEXP-551
CD8+CD28+
1
E-MEXP-2345
CD8+CD28-
1
E-MEXP-2345
65 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2280, E-GEOD-16363, E-GEOD-5370, ... (52 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-37
glioblastoma
3
E-GEOD-4290, E-GEOD-4412, E-MTAB-37
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
obesity
2
E-GEOD-2508, E-MTAB-62
control
2
E-GEOD-21912, E-GEOD-16363
lymphoma
2
E-MTAB-37, E-MTAB-62
169 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (25 experiments)

Factor Value U/D Experiments
unknown
1
E-GEOD-7307
CNOT7+CNOT8
1
1
E-MEXP-2218
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-GEOD-5230
glucose
1
E-MEXP-941
ethanol
1
E-MEXP-2241
34 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-MEXP-2283, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-MEXP-2280, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-20847, E-MEXP-2340, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-MEXP-1437, E-TABM-36, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-TABM-127, E-GEOD-20540, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-1290, E-MEXP-1956, ... (23 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Processing time: 0.286 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM